Effectiveness of the 23-valent polysaccharide pneumococcal vaccine against invasive pneumococcal disease in people 60 years or older
about
Bacterial and viral infections associated with influenza.The response to vaccination against influenza A(H1N1) 2009, seasonal influenza and Streptococcus pneumoniae in adult outpatients with ongoing treatment for cancer with and without rituximab.A population-based study on the impact of hospitalization for pneumonia in different age groups.Adult immunization with 13-valent pneumococcal vaccine in Campania region, South Italy: an economic evaluation.Correlation between in vitro complement deposition and passive mouse protection of anti-pneumococcal surface protein A monoclonal antibodies.Cost of pneumococcal infections and cost-effectiveness analysis of pneumococcal vaccination at risk adults and elderly in Turkey.Heterogeneity of the efficacy of the 23-valent pneumococcal polysaccharide vaccine caused by various underlying conditions of chronic pulmonary disease in older patients: prospective cohort study.Cost-effectiveness analysis of pneumococcal polysaccharide vaccination from age 60 in São Paulo State, Brazil.Higher levels of mucosal antibody to pneumococcal vaccine candidate proteins are associated with reduced acute otitis media caused by Streptococcus pneumoniae in young children.Pneumococcal Conjugated Vaccine Reduces the High Mortality for Community-Acquired Pneumonia in the Elderly: an Italian Regional Experience.Acute exercise enhancement of pneumococcal vaccination response: a randomised controlled trial of weaker and stronger immune responseEffectiveness of 23-valent pneumococcal polysaccharide vaccine on diabetic elderly.Comparison of immunogenicity and safety of an influenza vaccine administered concomitantly with a 13-valent pneumococcal conjugate vaccine or 23-valent polysaccharide pneumococcal vaccine in the elderly.Pneumococcal polysaccharide vaccination for adults: new perspectives for Europe.Acute bacterial meningitis in infants and children: epidemiology and management.Bacterial meningitis in older adults.Racial/Ethnic Differences in Receipt of Influenza and Pneumococcal Vaccination among Long-Stay Nursing Home Residents.Epidemiological characteristics associated with uptake of pneumococcal vaccine among older adults living in the community in Singapore: Results from the National Health Surveillance Survey 2013.Bacteria in COPD; their potential role and treatment.Effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive disease and hospital-treated pneumonia among people aged ≥65 years: a retrospective case-control study.[Pneumococcal vaccination for prevention of pneumonia].[From Müsli to the scalpel against chronic constipation: what regulates the intestine].The full benefits of adult pneumococcal vaccination: A systematic review.[Vaccination in advanced age].
P2860
Q30353612-E7E56F89-8500-435C-80EC-AF8E535CA6FFQ30362892-292B1C11-F99F-49B9-9E92-F841727EEBB6Q34184995-B22CE3E9-01D5-4FA9-B61F-3B8978C4C368Q34290690-F1AEB7BE-28F0-47F4-ABF5-510F369EC565Q34784957-D24F8FD5-BFD3-48C0-996D-6026EA82BC61Q35194846-26F466D9-E189-464B-B446-452D431D9852Q35319990-5E7B146C-254E-4747-919F-E8BA90A51189Q35667357-064C530D-D8AC-49AE-8DEC-B082DF13715FQ35915846-AB25C798-23BF-46C9-B6AA-2018A13356D6Q36192851-0BCBCDAB-51F2-46B7-B024-DBDCB58F9A8EQ36275718-81C470B2-4E93-46E9-8781-ED6F1AF863DCQ37078104-2F2C953F-DF5E-4F82-A33A-929B6C9A5379Q37625249-0699569A-189C-4379-8A82-697DC494546CQ37910264-618A95CE-8EA0-4866-BCA1-95AD65E4A453Q37945754-31A7A193-D7D3-4C67-8DA7-93684D1C0425Q38117051-C5850FDC-AC9C-4CD8-8446-A9A69B9A0549Q38600662-C6177F57-5ED2-408D-A3E6-1CB9C9B4A29BQ38682198-1A125B89-CB1E-46BD-B007-CDAC26CEA0DFQ38846409-D122AF13-E2AB-4868-89A7-D5B2CAC81286Q39041235-F0626695-95F3-4BA8-AE57-1F3138F2C732Q41331046-CD58C75A-4CD6-4668-95C0-57B4C4029C94Q43900855-6E825F82-2593-4BF0-8085-76EECDBDEB62Q47098784-EA340E2C-07FC-4078-9104-CCA067C18B06Q49915269-6351DEEB-8902-4F3F-ACC7-B6DCABEE080F
P2860
Effectiveness of the 23-valent polysaccharide pneumococcal vaccine against invasive pneumococcal disease in people 60 years or older
description
2010 nî lūn-bûn
@nan
2010 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մարտին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Effectiveness of the 23-valent ...... se in people 60 years or older
@ast
Effectiveness of the 23-valent ...... se in people 60 years or older
@en
Effectiveness of the 23-valent ...... e in people 60 years or older.
@nl
type
label
Effectiveness of the 23-valent ...... se in people 60 years or older
@ast
Effectiveness of the 23-valent ...... se in people 60 years or older
@en
Effectiveness of the 23-valent ...... e in people 60 years or older.
@nl
prefLabel
Effectiveness of the 23-valent ...... se in people 60 years or older
@ast
Effectiveness of the 23-valent ...... se in people 60 years or older
@en
Effectiveness of the 23-valent ...... e in people 60 years or older.
@nl
P2093
P2860
P50
P356
P1476
Effectiveness of the 23-valent ...... se in people 60 years or older
@en
P2093
Cruz M Fuentes
EPIVAC Study Group
Elisabet Salsench
Jorge A Guzmán
P2860
P2888
P356
10.1186/1471-2334-10-73
P577
2010-03-18T00:00:00Z
P5875
P6179
1047624407